Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.

Goldenberg DM, Stein R, Sharkey RM.

Oncotarget. 2018 Jun 22;9(48):28989-29006. doi: 10.18632/oncotarget.25615. eCollection 2018 Jun 22. Review.

2.

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.

Han C, Bellone S, Schwartz PE, Govindan SV, Sharkey RM, Goldenberg DM, Santin AD.

Gynecol Oncol Rep. 2018 May 23;25:37-40. doi: 10.1016/j.gore.2018.05.009. eCollection 2018 Aug.

3.

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130).

Sharkey RM, Govindan SV, Cardillo TM, Donnell J, Xia J, Rossi EA, Chang CH, Goldenberg DM.

Mol Cancer Ther. 2018 Jan;17(1):196-203. doi: 10.1158/1535-7163.MCT-17-0442. Epub 2017 Oct 27.

PMID:
29079710
4.

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD.

J Clin Oncol. 2017 Oct 10;35(29):3338-3346. doi: 10.1200/JCO.2017.73.9011. Epub 2017 Aug 17.

PMID:
28817371
5.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.

Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5.

PMID:
28679770
6.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM.

Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.

PMID:
28558150
7.

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR.

J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26.

PMID:
28548889
8.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

9.

Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.

Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM.

Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.

10.

Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.

Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F.

J Nucl Med. 2016 Oct;57(10):1505-1511. Epub 2016 May 26.

11.

Prospects and progress of antibody-drug conjugates in solid tumor therapies.

Govindan SV, Sharkey RM, Goldenberg DM.

Expert Opin Biol Ther. 2016 Jul;16(7):883-93. doi: 10.1517/14712598.2016.1173203. Epub 2016 May 3. Review.

PMID:
27045979
12.

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients.

Bodet-Milin C, Ferrer L, Rauscher A, Masson D, Rbah-Vidal L, Faivre-Chauvet A, Cerato E, Rousseau C, Hureaux J, Couturier O, Salaün PY, Goldenberg DM, Sharkey RM, Kraeber-Bodéré F, Barbet J.

Front Med (Lausanne). 2015 Nov 27;2:84. doi: 10.3389/fmed.2015.00084. eCollection 2015.

13.

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST.

Clin Genitourin Cancer. 2016 Feb;14(1):e75-9. doi: 10.1016/j.clgc.2015.10.002. Epub 2015 Oct 19.

14.

Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy.

Woliner-van der Weg W, Schoffelen R, Hobbs RF, Gotthardt M, Goldenberg DM, Sharkey RM, Slump CH, van der Graaf WT, Oyen WJ, Boerman OC, Sgouros G, Visser EP.

EJNMMI Phys. 2015 Dec;2(1):5. doi: 10.1186/s40658-014-0104-x. Epub 2015 Feb 24.

15.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.

16.

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).

Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM.

Clin Cancer Res. 2015 Nov 15;21(22):5131-8. doi: 10.1158/1078-0432.CCR-15-0670. Epub 2015 Jun 23.

17.

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM.

Oncotarget. 2015 Sep 8;6(26):22496-512.

18.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2015 Sep 1;21(17):3870-8. doi: 10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5.

19.

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.

Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM.

Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8.

PMID:
25915780
20.

A pretargeting system for tumor PET imaging and radioimmunotherapy.

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Frampas E, Faivre-Chauvet A, Rauscher A, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J.

Front Pharmacol. 2015 Mar 31;6:54. doi: 10.3389/fphar.2015.00054. eCollection 2015. Review.

21.

Overweight is not associated with cortical thickness alterations in children.

Sharkey RJ, Karama S, Dagher A.

Front Neurosci. 2015 Feb 4;9:24. doi: 10.3389/fnins.2015.00024. eCollection 2015.

22.

Clinical characteristics and outcomes for patients with an initial emergency presentation of malignancy: a 15 month audit of patient level data.

Savage P, Sharkey R, Kua T, Papanastasopoulos P, McDonald-Burrows Z, Hassan S, Probst F, Sanders A, Millington H.

Cancer Epidemiol. 2015 Feb;39(1):86-90. doi: 10.1016/j.canep.2014.11.001. Epub 2014 Dec 1.

PMID:
25475064
23.

Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.

Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, Sharkey RM, Goldenberg DM.

Mol Pharm. 2015 Jun 1;12(6):1836-47. doi: 10.1021/mp5006195. Epub 2014 Nov 25.

PMID:
25402018
24.

Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer.

Lütje S, Rijpkema M, Goldenberg DM, van Rij CM, Sharkey RM, McBride WJ, Franssen GM, Frielink C, Helfrich W, Oyen WJ, Boerman OC.

Cancer Res. 2014 Nov 1;74(21):6216-23. doi: 10.1158/0008-5472.CAN-14-0594. Epub 2014 Sep 24.

25.

Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.

van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Lütje S, McBride WJ, Oyen WJ, Boerman OC.

Cancer Biother Radiopharm. 2014 Oct;29(8):323-9. doi: 10.1089/cbr.2014.1660. Epub 2014 Sep 16.

26.

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.

Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA, Goldenberg DM.

Haematologica. 2014 Nov;99(11):1738-45. doi: 10.3324/haematol.2014.112110. Epub 2014 Aug 22.

27.

Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.

van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Franssen GM, Lütje S, McBride WJ, Oyen WJ, Boerman OC.

Mol Imaging Biol. 2015 Feb;17(1):94-101. doi: 10.1007/s11307-014-0772-x.

PMID:
25060065
28.

Al¹⁸F Labeling of Affibody Molecules.

McBride WJ, Goldenberg DM, Sharkey RM.

J Nucl Med. 2014 Jun;55(6):1043. doi: 10.2967/jnumed.113.134924. Epub 2014 Apr 24. No abstract available.

29.

Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.

Schoffelen R, Woliner-van der Weg W, Visser EP, Goldenberg DM, Sharkey RM, McBride WJ, Chang CH, Rossi EA, van der Graaf WT, Oyen WJ, Boerman OC.

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1593-602. doi: 10.1007/s00259-014-2742-6. Epub 2014 Mar 19.

PMID:
24643780
30.

Al(18) F labeling of peptides and proteins.

Laverman P, McBride WJ, Sharkey RM, Goldenberg DM, Boerman OC.

J Labelled Comp Radiopharm. 2014 Apr;57(4):219-23. doi: 10.1002/jlcr.3161. Epub 2014 Jan 10. Review.

PMID:
24408125
31.

Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.

Lütje S, Franssen GM, Sharkey RM, Laverman P, Rossi EA, Goldenberg DM, Oyen WJ, Boerman OC, McBride WJ.

Bioconjug Chem. 2014 Feb 19;25(2):335-41. doi: 10.1021/bc4004926. Epub 2014 Jan 8.

PMID:
24382090
32.

Malignant spinal cord compression: NICE guidance, improvements and challenges.

Savage P, Sharkey R, Kua T, Schofield L, Richardson D, Panchmatia N, Papanastasopoulos P, Williams M, Falconer A, Power D, Arnold F, Ulbricht C.

QJM. 2014 Apr;107(4):277-82. doi: 10.1093/qjmed/hct244. Epub 2013 Dec 11.

PMID:
24336849
33.

Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results.

Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, McBride WJ, Chang CH, Rossi EA, van der Graaf WT, Oyen WJ.

Br J Cancer. 2013 Aug 20;109(4):934-42. doi: 10.1038/bjc.2013.376. Epub 2013 Jul 16.

34.

Hypopituitarism as the presenting feature of bronchogenic carcinoma with metastases to the pituitary gland.

Johnston PC, Black NR, McIlroy J, Sharkey R, Garvey A, Lindsay JR.

Indian J Endocrinol Metab. 2013 Jan;17(1):167-9. doi: 10.4103/2230-8210.107876.

35.

Al18F: a new standard for radiofluorination.

Goldenberg DM, Sharkey RM, McBride WJ, Boerman OC.

J Nucl Med. 2013 Jul;54(7):1170. doi: 10.2967/jnumed.113.125245. Epub 2013 May 17. No abstract available.

36.

Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.

van Rij CM, Lütje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, McBride WJ, Rossi EA, Oyen WJ, Boerman OC.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1377-83. doi: 10.1007/s00259-013-2434-7. Epub 2013 May 15.

PMID:
23674207
37.

Radiofluorination using aluminum-fluoride (Al18F).

McBride WJ, Sharkey RM, Goldenberg DM.

EJNMMI Res. 2013 May 8;3(1):36. doi: 10.1186/2191-219X-3-36.

38.

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.

Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM.

Mol Cancer Ther. 2013 Jun;12(6):968-78. doi: 10.1158/1535-7163.MCT-12-1170. Epub 2013 Feb 20.

39.

Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer.

Schoffelen R, van der Graaf WT, Sharkey RM, Franssen GM, McBride WJ, Chang CH, Bos DL, Goldenberg DM, Oyen WJ, Boerman OC.

J Nucl Med. 2012 Dec;53(12):1926-32. doi: 10.2967/jnumed.112.106278. Epub 2012 Oct 18.

40.

A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.

Sharkey RM, van Rij CM, Karacay H, Rossi EA, Frielink C, Regino C, Cardillo TM, McBride WJ, Chang CH, Boerman OC, Goldenberg DM.

J Nucl Med. 2012 Oct;53(10):1625-32. doi: 10.2967/jnumed.112.104364. Epub 2012 Sep 5.

41.

Recent progress in cancer therapy with radiolabeled monoclonal antibodies.

Goldenberg DM, Sharkey RM.

Ther Deliv. 2011 Jun;2(6):675-9.

PMID:
22822500
42.

Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.

Salaun PY, Campion L, Bournaud C, Faivre-Chauvet A, Vuillez JP, Taieb D, Ansquer C, Rousseau C, Borson-Chazot F, Bardet S, Oudoux A, Cariou B, Mirallié E, Chang CH, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F.

J Nucl Med. 2012 Aug;53(8):1185-92. doi: 10.2967/jnumed.111.101865. Epub 2012 Jun 28.

43.

Pretargeted molecular imaging and radioimmunotherapy.

Goldenberg DM, Chang CH, Rossi EA, J W, McBride, Sharkey RM.

Theranostics. 2012;2(5):523-40. doi: 10.7150/thno.3582. Epub 2012 May 17.

44.

Using antibodies to target cancer therapeutics.

Goldenberg DM, Sharkey RM.

Expert Opin Biol Ther. 2012 Sep;12(9):1173-90. doi: 10.1517/14712598.2012.693472. Epub 2012 Jun 1. Review.

PMID:
22650606
45.

Pretargeting: taking an alternate route for localizing radionuclides.

Sharkey RM, Chang CH, Rossi EA, McBride WJ, Goldenberg DM.

Tumour Biol. 2012 Jun;33(3):591-600. doi: 10.1007/s13277-012-0367-6. Epub 2012 Mar 7. Review.

PMID:
22396041
46.

Voxel-based relaxometry for cases of an unresolved epilepsy diagnosis.

Kosior RK, Sharkey R, Frayne R, Federico P.

Epilepsy Res. 2012 Mar;99(1-2):46-54. doi: 10.1016/j.eplepsyres.2011.10.015. Epub 2012 Feb 17.

PMID:
22342566
47.

Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method.

Schoffelen R, van der Graaf WT, Sharkey RM, Franssen GM, McBride WJ, Chang CH, Laverman P, Goldenberg DM, Oyen WJ, Boerman OC.

EJNMMI Res. 2012 Jan 27;2:5. doi: 10.1186/2191-219X-2-5.

48.

New lyophilized kit for rapid radiofluorination of peptides.

McBride WJ, D'Souza CA, Karacay H, Sharkey RM, Goldenberg DM.

Bioconjug Chem. 2012 Mar 21;23(3):538-47. doi: 10.1021/bc200608e. Epub 2012 Feb 10.

49.

Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.

Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM.

Mol Cancer Ther. 2012 Jan;11(1):224-34. doi: 10.1158/1535-7163.MCT-11-0632. Epub 2011 Oct 28.

50.

Optimized labeling of NOTA-conjugated octreotide with F-18.

Laverman P, D'Souza CA, Eek A, McBride WJ, Sharkey RM, Oyen WJ, Goldenberg DM, Boerman OC.

Tumour Biol. 2012 Apr;33(2):427-34. doi: 10.1007/s13277-011-0250-x. Epub 2011 Oct 19.

Supplemental Content

Loading ...
Support Center